Targeting ErbB-1 and ErbB-4 in irradiated head and neck cancer: Results of in vitro and in vivo studies

Head and Neck

Volumn 35, Issue 3, 2013, Pages 399-407

  Barnea, Itay ^a   Haif, Sasha ^a   Keshet, Rom ^a   Karaush, Vicky ^a   Lev Ari, Shahar ^a   Khafif, Avi ^a   Shtabsky, Alexander ^a   Yarden, Yosef ^b   Vexler, Akiva ^a   Yosef, Rami Ben ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

anti ErbB 4 antibody; cetuximab; combined therapy; head and neck cancer; radiation

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RADIATION DOSE; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874116478     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.22967     Document Type: Article

References (29)

1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-28.
2. Mosesson Y, Yarden Y,. Oncogenic growth factor receptors: implications for signal transduction therapy. Semin Cancer Biol 2004; 14: 262-270.
3. Earp HS III, Calvo BF, Sartor CI,. The EGF receptor family-multiple roles in proliferation, differentiation, and neoplasia with an emphasis on HER4. Trans Am Clin Climatol Assoc 2003; 114: 315-333; discussion 333-334.
4. Yarden Y, Sliwkowski MX,. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
5. Grandis JR, Tweardy DJ,. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53: 3579-3584.
6. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-5587.
7. Herbst RS, Hong WK,. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer. Semin Oncol 2002; 29 (5 Suppl 14): 18-30.
8. Hilgers RD, Newlands ES, Hoffman R, Mitchell H, Bagshawe KD,. Correlation of plasma methotrexate concentration with human chorionic gonadotropin and therapeutic response to low-dose methotrexate-citrovorum factor in low-medium-risk gestational trophoblastic tumors. Gynecol Oncol 1991; 41: 117-122.
9. Huang SM, Harari PM,. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000; 6: 2166-2174.
10. Shin DM, Ro JY, Hong WK, Hittelman WN,. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 3153-3159.
11. Mizuno H, Itoi Y, Kawahara S, Ogawa R, Akaishi S, Hyakusoku H,. In vivo adipose tissue regeneration by adipose-derived stromal cells isolated from GFP transgenic mice. Cells Tissues Organs 2008; 187: 177-185.
12. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177.
13. Rubin Grandis J, Tweardy DJ, Melhem MF,. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck squamous cell carcinoma. Clin Cancer Res 1998; 4: 13-20.
14. Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RC, Angus B,. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4. J Clin Pathol 2003; 56: 300-304.
15. Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM,. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 2003; 200: 290-297.
16. Ben-Yosef R, Starr A, Karaush V, et al. ErbB-4 may control behavior of prostate cancer cells and serve as a target for molecular therapy. Prostate 2007; 67: 871-880.
17. Bowers G, Reardon D, Hewitt T, et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 2001; 20: 1388-1397.
18. Fallon KB, Havlioglu N, Hamilton LH, Cheng TP, Carroll SL,. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line. J Neurooncol 2004; 66: 273-284.
19. Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ,. ErbB kinases and NDF signaling in human prostate cancer cells. Oncogene 1997; 15: 2705-2716.
20. Siegall CB, Bacus SS, Cohen BD, et al. HER4 expression correlates with cytotoxicity directed by a heregulin-toxin fusion protein. J Biol Chem 1995; 270: 7625-7630.
21. Starr A, Greif J, Vexler A, et al. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int J Cancer 2006; 119: 269-274.
22. Gurevich O, Vexler A, Marx G, et al. Fibrin microbeads for isolating and growing bone marrow-derived progenitor cells capable of forming bone tissue. Tissue Eng 2002; 8: 661-672.
23. Williams EE, Trout LJ, Gallo RM, et al. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. Cancer Lett 2003; 192: 67-74.
24. Gorodetsky R, Mou X, Pfeffer MR, Peretz T, Levy-Agababa F, Vexler AM,. Sub-additive effect of the combination of radiation and cisplatin in cultured murine and human cell lines. Isr J Med Sci 1995; 31: 95-100.
25. Gorodetsky R, Levy-Agababa F, Mou X, Vexler AM,. Combination of cisplatin and radiation in cell culture: effect of duration of exposure to drug and timing of irradiation. Int J Cancer 1998; 75: 635-642.
26. Merimsky O, Staroselsky A, Inbar M, et al. Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer. Ann Oncol 2001; 12: 1127-1131.
27. Ben-Yosef R, Sarid D, Vexler A, et al. Nuclear and cytoplasmic expression of ErbB-4 in prostate cancer. Int J Biol Markers 2007; 22: 181-185.
28. de Vicente JC, Esteban I, Germanà P, Germanà A, Vega JA,. Expression of ErbB-3 and ErbB-4 protooncogene proteins in oral squamous cell carcinoma: a pilot study. [Article in English, Spanish] Med Oral 2003; 8: 374-381.
29. Ben-Yosef RM, Starr A, Matceyevsky D, Khafif A, Vexler A,. ErbB-4 expression in squamous cell carcinoma of head and neck. Targeted Oncol 2006; 1: 181-185.